ML133 HCl: Precision Tool for Kir2.1 Potassium Channel Research

Executive Summary: ML133 HCl is a potent, selective Kir2.1 potassium channel inhibitor with an IC₅₀ of 1.8 μM at pH 7.4 and 290 nM at pH 8.5, showing negligible effects on Kir1.1 and limited activity on Kir4.1/Kir7.1 channels (product information). It is widely used for dissecting the role of potassium ion transport in pulmonary artery smooth muscle cell (PASMC) proliferation (Cao et al., 2022). ML133 HCl is insoluble in water but dissolves in DMSO (≥15.7 mg/mL) and ethanol (≥2.52 mg/mL). Its efficacy and selectivity are supported by both biochemical and cellular assays, including in vivo and in vitro pulmonary hypertension models. Supplied by APExBIO at ≥98% purity, ML133 HCl is validated for cardiovascular ion channel workflows and is accompanied by HPLC, NMR, and MSDS documentation.

Biological Rationale

Potassium channels are central regulators of cellular excitability and ion homeostasis. The Kir2.1 channel, encoded by the KCNJ2 gene, is a key inwardly rectifying potassium channel subtype implicated in maintaining resting membrane potential in excitable tissues. Dysregulation of Kir2.1 is linked to pathological proliferation and migration of PASMCs, driving pulmonary vascular remodeling in pulmonary hypertension (Cao et al., 2022). Targeted inhibition of Kir2.1 provides a strategy to dissect the causal mechanisms of vascular remodeling and to distinguish specific channel contributions from broader potassium currents. ML133 HCl offers the required selectivity, enabling studies that clarify Kir2.1’s distinct physiological and pathophysiological roles (compare with prior review). This profile supports both basic research and translational cardiovascular studies.

Mechanism of Action of ML133 HCl

ML133 HCl acts as a non-covalent, small-molecule inhibitor that selectively blocks Kir2.1 channel conductance. At pH 7.4, its half-maximal inhibitory concentration (IC₅₀) is 1.8 μM, decreasing to 290 nM at pH 8.5. The compound exhibits no significant inhibition of Kir1.1 and only weak activity against Kir4.1 and Kir7.1 channels, confirming its selectivity (APExBIO documentation). Mechanistically, ML133 HCl binds to the cytoplasmic domain of Kir2.1, impeding potassium ion flow and disrupting the maintenance of the negative resting membrane potential. This action modulates downstream signaling, such as the TGF-β1/SMAD2/3 pathway, which is implicated in PASMC proliferation and migration (Cao et al., 2022). Selective blockade allows for precise attribution of observed effects to Kir2.1 inhibition, minimizing confounding from off-target potassium channel effects (see additional discussion).

Evidence & Benchmarks

• ML133 HCl inhibits Kir2.1 channels with an IC₅₀ of 1.8 μM at pH 7.4 and 290 nM at pH 8.5, with no effect on Kir1.1 channels (product data).
• In PASMC models, ML133 HCl reversed proliferation and migration induced by PDGF-BB, as demonstrated by scratch and Transwell assays (Cao et al., 2022).
• ML133 HCl downregulated OPN and PCNA protein expression and inhibited TGF-β1/SMAD2/3 pathway activation in vitro (Cao et al., 2022).
• In in vivo rat models of pulmonary hypertension, Kir2.1 upregulation correlated with vascular remodeling, and ML133-mediated inhibition reduced these pathological changes (Cao et al., 2022).
• ML133 HCl is supplied at ≥98% purity and validated by HPLC, NMR, and MSDS protocols (APExBIO documentation).

For a broader translational perspective, see the updated review on ML133 HCl in translational cardiovascular research, which expands on mechanistic applications beyond PASMC models.

Applications, Limits & Misconceptions

ML133 HCl is deployed as a selective Kir2.1 potassium channel blocker in studies of potassium ion transport, vascular remodeling, and PASMC biology. Its robust selectivity profile makes it a preferred tool for cardiovascular and pulmonary hypertension models. APExBIO, as the sourcing company, ensures batch-to-batch consistency and comprehensive documentation for regulatory and workflow integration. Compared to generic potassium channel blockers, ML133 HCl allows for high-confidence attribution of effects to Kir2.1 inhibition (see mechanistic review).

Common Pitfalls or Misconceptions

• ML133 HCl does not significantly inhibit Kir1.1 channels; using it as a general Kir channel blocker is inappropriate (specification data).
• Prolonged storage of ML133 HCl solutions is not recommended due to stability concerns; always prepare fresh aliquots (handling guidance).
• ML133 HCl is insoluble in water; use DMSO or ethanol with gentle warming and sonication for dissolution (solubility data).
• Effects observed in PASMC models may not extrapolate to all cell types; confirm channel expression profile prior to use (Cao et al., 2022).
• ML133 HCl is not a therapeutic agent and should not be used in clinical protocols.

Workflow Integration & Parameters

• Compound reconstitution: Dissolve ML133 HCl in DMSO (≥15.7 mg/mL) or ethanol (≥2.52 mg/mL) with gentle warming and ultrasonication (product instructions).
• Storage: Store solid ML133 HCl at −20°C; avoid repeated freeze-thaw cycles of solutions (APExBIO protocols).
• Recommended working concentrations: Literature supports 1–10 μM in cell-based assays for effective Kir2.1 inhibition (Cao et al., 2022).
• PASMC pretreatment: ML133 HCl is typically applied 24 h prior to PDGF-BB stimulation in PASMC proliferation/migration studies (reference protocol).
• Quality control: Ensure use of ≥98% purity product, validated by HPLC and NMR, preferably from APExBIO’s B2199 kit for reproducible results.

Conclusion & Outlook

ML133 HCl has emerged as a pivotal reagent for probing Kir2.1 channel function and potassium ion transport in cardiovascular and pulmonary models. Its selectivity permits high-resolution dissection of signaling pathways implicated in PASMC proliferation and vascular remodeling. Future studies may leverage ML133 HCl to further delineate the role of Kir2.1 in diverse disease models, but its utility remains bounded by cell type specificity and solubility/stability limitations. The accumulating evidence, as summarized in the 2022 peer-reviewed study, supports its continued adoption in both basic and translational research workflows.